Literature DB >> 18322057

Evaluation of the new Micronaut-Candida system compared to the API ID32C method for yeast identification.

Z Szabó1, B Tóth, M Kovács, G Kardos, A Maráz, F Rozgonyi, L Majoros.   

Abstract

A new system, Micronaut-Candida, was compared to API ID32C to identify 264 yeast (Candida albicans, C. parapsilosis, C. tropicalis, C. krusei, C. inconspicua, C. norvegensis, C. lusitaniae, C. guilliermondii, C. dubliniensis, C. pulcherrima, C. famata, C. rugosa, C. glabrata, C. kefyr, C. lipolytica, C. catenulata, C. neoformans, Geotrichum and Trichosporon species, Rhodotorula glutinis, and Saccharomyces cerevisiae) clinical isolates. Results were in concordance in 244 cases. Eighteen out of the 20 of discordant results were correctly identified by Micronaut-Candida but not by API ID32C, as confirmed by PCR ribotyping.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18322057      PMCID: PMC2395094          DOI: 10.1128/JCM.02350-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

Review 1.  Antifungal drug resistance of pathogenic fungi.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

2.  Rapid discrimination between Candida albicans and Candida dubliniensis by using real-time polymerase chain reaction.

Authors:  Ferenc Somogyvari; Ilona Doczi; Julianna Serly; Suhail Ahmad; Elizabeth Nagy
Journal:  Diagn Microbiol Infect Dis       Date:  2007-03-26       Impact factor: 2.803

3.  Efficacy of API 20C and ID 32C systems for identification of common and rare clinical yeast isolates.

Authors:  R Ramani; S Gromadzki; D H Pincus; I F Salkin; V Chaturvedi
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

4.  Evaluation of the new API Candida system for identification of the most clinically important yeast species.

Authors:  S Bernal; E Martín Mazuelos; M Chávez; J Coronilla; A Valverde
Journal:  Diagn Microbiol Infect Dis       Date:  1998-11       Impact factor: 2.803

5.  Comparison of the new API Candida system to the ID 32C system for identification of clinically important yeast species.

Authors:  H Fricker-Hidalgo; O Vandapel; M A Duchesne; M A Mazoyer; D Monget; B Lardy; B Lebeau; J Freney; P Ambroise-Thomas; R Grillot
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

6.  Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III.

Authors:  Arianna Tavanti; Amanda D Davidson; Neil A R Gow; Martin C J Maiden; Frank C Odds
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

7.  Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

Authors:  Sofia Perea; José L López-Ribot; Brian L Wickes; William R Kirkpatrick; Olga P Dib; Stefano P Bachmann; Suzanne M Keller; Marcos Martinez; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

9.  In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; R J Hollis; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2004-02       Impact factor: 2.803

10.  Restriction enzyme analysis of ribosomal DNA shows that Candida inconspicua clinical isolates can be misidentified as Candida norvegensis with traditional diagnostic procedures.

Authors:  L Majoros; G Kardos; A Belák; A Maráz; L Asztalos; E Csánky; Z Barta; B Szabó
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

View more
  7 in total

1.  Killing rates for caspofungin against Candida albicans after brief and continuous caspofungin exposure in the presence and absence of serum.

Authors:  Renátó Kovács; Rudolf Gesztelyi; David S Perlin; Gábor Kardos; Marianna Domán; Réka Berényi; László Majoros
Journal:  Mycopathologia       Date:  2014-08-15       Impact factor: 2.574

2.  Candida palmioleophila: characterization of a previously overlooked pathogen and its unique susceptibility profile in comparison with five related species.

Authors:  Rasmus H Jensen; Maiken C Arendrup
Journal:  J Clin Microbiol       Date:  2010-12-08       Impact factor: 5.948

Review 3.  Candida dubliniensis: epidemiology and phenotypic methods for identification.

Authors:  Erico Silva Loreto; Liliane A Scheid; Cristina W Nogueira; Gilson Zeni; Janio M Santurio; Sydney H Alves
Journal:  Mycopathologia       Date:  2010-02-21       Impact factor: 2.574

Review 4.  Uncommon opportunistic fungal infections of oral cavity: A review.

Authors:  Ag Deepa; Bindu J Nair; Tt Sivakumar; Anna P Joseph
Journal:  J Oral Maxillofac Pathol       Date:  2014-05

5.  COMPARISON BETWEEN FOUR USUAL METHODS OF IDENTIFICATION OF Candida SPECIES.

Authors:  Margarida Neves Souza; Stéfanie Otowicz Ortiz; Marcelo Martins Mello; Flávio de Mattos Oliveira; Luiz Carlos Severo; Cristine Souza Goebel
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015 Jul-Aug       Impact factor: 1.846

Review 6.  Current Aspects in the Biology, Pathogeny, and Treatment of Candida krusei, a Neglected Fungal Pathogen.

Authors:  Manuela Gómez-Gaviria; Héctor M Mora-Montes
Journal:  Infect Drug Resist       Date:  2020-06-10       Impact factor: 4.003

7.  In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae.

Authors:  Zoltán Tóth; Lajos Forgács; Jeffrey B Locke; Gábor Kardos; Fruzsina Nagy; Renátó Kovács; Adrien Szekely; Andrew M Borman; László Majoros
Journal:  J Antimicrob Chemother       Date:  2019-12-01       Impact factor: 5.790

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.